Clinical Trial Goal
To find out:
- The highest dose of MT-401-OTS that's safe to give
- If MT-401-OTS is safe and works well to treat AML or MDS in older adults
You may be able to join this trial if you:
- Are 65 years old or older
- Have AML or MDS
- Do not have acute promyelocytic leukemia
- Have not had an allogeneic (cells from a donor) or autologous (your own cells) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
MT-401-OTS is a type of T-cell therapy that targets and attacks specific antigens on tumor cells.
You’ll get:
You’ll get:
- MT-401-OTS – Given as an intravenous (IV) infusion. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has not yet approved MT-401-OTS.
Contacts
Patricia Allison, BS, 713-400-6400, pallison@markertherapeutics.com
Beth Lepping, BSN, 713-400-6400, elepping@markertherapeutics.com
Locations
City of Hope Center (City of Hope National Medical Center, City of Hope Medical Center)RECRUITING
Duarte, California
Stephanie Kasten, 626-215-2835, skasten@coh.org
Moffitt Cancer CenterRECRUITING
Tampa, Florida
Sarah Starr, 813-745-2690, sarah.starr@moffitt.org
KU Cancer CenterRECRUITING
Kansas City, Kansas
Rafaela Nelson, 913-945-9226, rbarbosafernandes@kumc.edu
Sponsors
collaborator: University of Kansas Medical Center, collaborator: H. Lee Moffitt Cancer Center and Research Institute, collaborator: City of Hope National Medical Center, collaborator: FDA Office of Orphan Products Development, lead: Marker Therapeutics, Inc.
